Merrill retains Alizyme at buy

Alizyme plc was retained at a buy rating by Merrill Lynch analyst Peter Welford on news that Takeda, Alizyme's licensee in Japan, is moving the anti-obesity drug cetilistat into phase 2 trials. Merrill sees cetilistat as a potential blockbuster with peak sales of $1.5 billion plus with a projected launch in late 2009. Shares of the Cambridge, England, biopharmaceutical company were up p3.50, or 2.65%, at p135.50. (London: AZM)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.